Allergan to acquire Repros Therapeutics for 67c per share
The company’s Board of Directors has unanimously approved the transaction.
Under the terms of the merger agreement, a subsidiary of Allergan will commence a cash tender offer to purchase all of the outstanding shares of Repros common stock for 67c per share. T
he closing of the tender offer is subject to customary closing conditions, including the tender of a majority of the outstanding shares of Repros common stock.
The merger agreement contemplates that Allergan, through its subsidiary, will acquire any shares of Repros that are not tendered into the offer through a second-step merger, which will be completed as soon as practicable following the closing of the tender offer.
Pending approvals, Repros anticipates the transaction will close during the first quarter of 2018.
RPRX closed at $0.47.
To read timely stories similar to this, along with money making trade ideas, sign up for a membership to Stockwinners.
This article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility.